A Review on Targeting Nanoparticles for Breast Cancer

Alqaraghuli, Hasanain Gomhor J.; Kashanian, Soheila; Rafipour, Ronak

doi:10.2174/1389201020666190731130001

Cited by 28 publications

(18 citation statements)

References 164 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early menarche, late menopause and obesity all increase women's risk factors for breast cancer [2,3]. Although chemotherapeutic drugs have been widely used to treat breast cancer, they are unable to distinguish between cancerous and noncancerous cells, which lead to hazardous side effects [4]. Targeted drug delivery, such as nanoparticles, for the treatment of breast cancer offers a lot of promise, both therapeutically and in pharmacological research.…”

Section: Introductionmentioning

confidence: 99%

The Impact of Improving Dermal Permeation on the Efficacy and Targeting of Liposome Nanoparticles as a Potential Treatment for Breast Cancer

et al. 2021

View full text Add to dashboard Cite

Breast cancer is the most frequent malignancy in women. This work focuses on developing deformable liposomes as a potential carrier for breast cancer treatment and studying the impact of improving dermal permeation on the efficacy and targeting of liposomes. Raloxifene (RXF), an oestrogen antagonist, was used as a model drug. Using Box–Behnken design, different formulations of RXF-loaded deformable liposome (RLDL) were prepared using different propylene glycol, phospholipid and cholesterol concentrations. The percentage of entrapment efficiency (Y1), particle size (Y2), zeta potential (Y3) and steady-state flux (Y4) of the prepared formulations were all evaluated. Y1 and Y4 were significantly increased and Y2 and Y3 were significantly decreased when the propylene glycol concentration was increased. The optimization was obtained and the optimum formulation was that including phospholipid (1.40% w/w), cholesterol (0.15% w/w) and propylene glycol (10% v/v). The selected optimum formulation displayed a % EE of 78.34 ± 1.04% with a steady-state flux of 4.21 ± 0.02 µg/cm2/h. In order to investigate bioavailability, antitumor effectiveness and permeation, the optimum formulation was selected and included in a carbopol gel. The optimum gel formulation had 2.77 times higher bioavailability and, as a result, considerable antitumor action as compared to oral RXF. In conclusion, optimum RLDL gel may be an effective breast cancer treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

The Impact of Improving Dermal Permeation on the Efficacy and Targeting of Liposome Nanoparticles as a Potential Treatment for Breast Cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…To overcome these issues, we incorporated PEG into our design, which enables steric stabilization of nanoparticles and prevents interaction of the nanoparticles with immune cells (48). Functionalizing nanoparticles with "self" markers or homing molecules can further improve the systemic delivery of nanoparticles (49).…”

Section: Discussionmentioning

confidence: 99%

Oncogenic TRIM37 Links Chemoresistance and Metastatic Fate in Triple-Negative Breast Cancer

et al. 2020

View full text Add to dashboard Cite

The majority of clinical deaths in patients with triple-negative breast cancer (TNBC) are due to chemoresistance and aggressive metastases, with high prevalence in younger women of African ethnicity. Although tumorigenic drivers are numerous and varied, the drivers of metastatic transition remain largely unknown. Here, we uncovered a molecular dependence of TNBC tumors on the TRIM37 network, which enables tumor cells to resist chemotherapeutic as well as metastatic stress. TRIM37-directed histone H2A monoubiquitination enforces changes in DNA repair that rendered TP53-mutant TNBC cells resistant to chemotherapy. Chemotherapeutic drugs triggered a positive feedback loop via ATM/E2F1/ STAT signaling, amplifying the TRIM37 network in chemoresistant cancer cells. High expression of TRIM37 induced transcriptomic changes characteristic of a metastatic phenotype, and inhibition of TRIM37 substantially reduced the in vivo propensity of TNBC cells. Selective delivery of TRIM37-specific antisense oligonucleotides using antifolate receptor 1-conjugated nanoparticles in combination with chemotherapy suppressed lung metastasis in spontaneous metastatic murine models. Collectively, these findings establish TRIM37 as a clinically relevant target with opportunities for therapeutic intervention.Significance: TRIM37 drives aggressive TNBC biology by promoting resistance to chemotherapy and inducing a prometastatic transcriptional program; inhibition of TRIM37 increases chemotherapy efficacy and reduces metastasis risk in patients with TNBC.

show abstract

“…Nanoparticles (NPs) (10 to 400 nm) have added a new dimension in the drug delivery concept, providing an unprecedented opportunity to revolutionize cancer therapy and management. The immense potentiality of NPs as a drug carrier for specific identification and destruction of cancer cells led to an increased interest to study various biocompatible and biodegradable nanocarriers for the delivery of anticancer agents both in preclinical and clinical trials [12][13][14]. Considering the drawbacks of conventional therapies, NP-based drug delivery is a useful toolkit particularly for site-specific drug delivery, improved drug accumulation in tumor site due to the enhanced permeability and retention (EPR) effect, and the capability to bypass the MDR effects of the breast cancer cell [15][16][17][18].…”

Section: Introductionmentioning

confidence: 99%

Nanoparticles Targeting Receptors on Breast Cancer for Efficient Delivery of Chemotherapeutics

2021

View full text Add to dashboard Cite

The journey of chemotherapeutic drugs from the site of administration to the site of action is confronted by several factors including low bioavailability, uneven distribution in major organs, limited accessibility of drug molecules to the distant tumor tissues, and lower therapeutic indexes. These unavoidable features of classical chemotherapeutics necessitate an additional high, repetitive dose of drugs to obtain maximum therapeutic responses with the result of unintended adverse side effects. An erratic tumor microenvironment, notable drawbacks of conventional chemotherapy, and multidrug-resistant mechanisms of breast cancer cells warrant precisely designed therapeutics for the treatment of cancers. In recent decades, nanoparticles have been deployed for the delivery of standard anticancer drugs to maximize the therapeutic potency while minimizing the adverse effects to increase the quality and span of life. Several organic and inorganic nanoplatforms that have been designed exploiting the distinctive features of the tumor microenvironment and tumor cells offer favorable physicochemical properties and pharmacokinetic profiles of a parent drug, with delivery of higher amounts of the drug to the pathological site and its controlled release, thereby improving the balance between its efficacy and toxicity. Advances to this front have included design and construction of targeted nanoparticles by conjugating homing devices like peptide, ligand, and Fab on the surface of nanomaterials to navigate nanoparticledrug complexes towards the target tumor cell with minimal destruction of healthy cells. Furthermore, actively targeting nanoparticles can facilitate the delivery and cellular uptake of nanoparticle-loaded drug constructs via binding with specific receptors expressed aberrantly on the surface of a tumor cell. Herein, we present an overview of the principle of targeted delivery approaches, exploiting drug-nanoparticle conjugates with multiple targeting moieties to target specific receptors of breast cancer cells and highlighting therapeutic evaluation in preclinical studies. We conclude that an understanding of the translational gap and challenges would show the possible future directions to foster the development of novel targeted nanotherapeutics.

show abstract

A Review on Targeting Nanoparticles for Breast Cancer

Cited by 28 publications

References 164 publications

The Impact of Improving Dermal Permeation on the Efficacy and Targeting of Liposome Nanoparticles as a Potential Treatment for Breast Cancer

The Impact of Improving Dermal Permeation on the Efficacy and Targeting of Liposome Nanoparticles as a Potential Treatment for Breast Cancer

Oncogenic TRIM37 Links Chemoresistance and Metastatic Fate in Triple-Negative Breast Cancer

Nanoparticles Targeting Receptors on Breast Cancer for Efficient Delivery of Chemotherapeutics

Contact Info

Product

Resources

About